Ellen Taylor, MD
Gynecology · Baltimore, MDNPI 1174597587
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,123 of the $1,317 with a category attached, or 85.3%. 12 manufacturers reported payments, led by Astellas Pharma US Inc at 24.5% of the total. Reporting peaked in 2019 at $356 and has fallen 76.0% since, to $86 in 2025.
Across 45 payments — averaging $29.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$323
- Amgen$320
- AbbVie$185
- Therapeuticsmd, Inc.$162
- Medtronic$92
- Pfizer$83
- plus $152 from 6 others
What the payments were for
- Food & beverage$1,12385%
- Education$19415%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 7 | $323 |
| Amgen | 3 | $320 |
| AbbVie(2 entities) | 10 | $185 |
| Therapeuticsmd, Inc. | 11 | $162 |
| Medtronic | 2 | $92 |
| Pfizer | 5 | $83 |
| Mayne Pharma Commercial LLC | 1 | $31 |
| Avion Pharmaceuticals | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Exact Sciences | 1 | $20 |
| Myovant Sciences Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolia$211
How this compares
$1,317 in reported general payments places this provider in the 65th percentile of 79 gynecology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 94 | $6,697 |
| ValacyclovirValacyclovir Hcl | 43 | $2,662 |
| Clobetasol Propionate | 34 | $1,227 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 60 | $706 |
| Betamethasone Valerate | 38 | $686 |
| Fluconazole | 11 | $66 |
Paid to pharmacies, not to this prescriber.
Other gynecology in Baltimore
- Vadim MorozovBaltimore$394K
- Ann PetersBaltimore$25K
- Farinaz SeifiBaltimore$17K
- Christine HelouBaltimore$11K
- Caroline GornBaltimore$2K
- Conrad DuncanBaltimore$2K
- Eleonora GokoyevaBaltimore$2K
- Michelle GermainBaltimore$1K
- Molly ClintonBaltimore$531
- Beth AronsonBaltimore$467
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.